Guidelines for clinical pharmacological practices in Huntington's disease

Area of Science:

• Neurology
• Pharmacology
• Rare Diseases

Background:

• Evidence-based medicine is difficult to achieve in rare diseases like Huntington's disease (HD) due to a lack of randomized controlled trials.
• Optimal pharmacological interventions for HD are crucial for patient care.

Purpose of the Study:

• To establish guidelines for optimizing pharmacological therapeutic interventions in Huntington's disease (HD).
• To leverage literature and expert opinion from the French National Huntington Disease Reference Centre.

Main Methods:

• Systematic literature analysis (1965-2013) by HD experts.
• Utilized a scoring procedure from the French National Authority for Health.
• Developed provisional guidelines, refined through online questionnaires and a multidisciplinary working group meeting.

Main Results:

• Tetrabenazine is the only intervention with evidence for chorea management.
• Second-generation antipsychotics are recommended for psychiatric manifestations (low evidence).
• Most guidelines are based on low-level evidence and limited professional agreement.

Conclusions:

• Patient care for HD has improved despite the absence of high-level evidence.
• Guidelines were developed using expert consensus from the French National Plan for Rare Diseases.
• International extension of this strategy is recommended to foster research and harmonize global HD care.